China-based Epigenic Therapeutics secured $60 million in a Series B financing to expedite clinical development of gene therapy candidates EPI-003 for chronic hepatitis B and EPI-001 for hypercholesterolemia. The company employs novel CRISPR-based epigenetic editing approaches aiming to achieve durable disease modification by targeting regulatory elements. This funding round supports translational and clinical programs positioning Epigenic among emerging leaders in advanced genetic medicine.